Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing single-arm study of emapalumab in previously treated Chinese patients with primary hemophagocytic lymphohistiocytosis
CTR20222253Phase 4Completed
- Sponsor
- Sobi
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of emapalumab in hereditary hemophagocytic lymphohistiocytosis (FHL), sponsored by Sobi. Started Feb 2023; status: completed.
02
Drugs
emapalumab
03
Conditions
hereditary hemophagocytic lymphohistiocytosis (FHL)
Beyond the preview
Go deeper on CTR20222253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222253.